TECHNETIUM TC 99M SULFUR COLLOID
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TECHNETIUM TC 99M SULFUR COLLOID (TECHNETIUM TC 99M SULFUR COLLOID).
Technetium Tc 99m sulfur colloid is a radiopharmaceutical that undergoes phagocytosis by the reticuloendothelial system (RES), primarily in the liver, spleen, and bone marrow. After intravenous administration, particles are trapped by macrophages, allowing imaging of these organs. For lymphoscintigraphy, it is injected subcutaneously or intradermally and migrates via lymphatic channels to localize sentinel lymph nodes.
| Metabolism | Technetium Tc 99m sulfur colloid is not metabolized; it is cleared from the blood by phagocytosis in the liver, spleen, and bone marrow. The decay of technetium-99m (half-life 6 hours) results in emission of gamma rays for imaging. The compound is eliminated via decay and excretion in urine. |
| Excretion | Primarily renal; ~50-70% excreted unchanged in urine within 24 hours; remainder eliminated via hepatobiliary system with fecal excretion of colloid particles trapped in liver and spleen |
| Half-life | Terminal elimination half-life of free pertechnetate is about 6 hours; for the colloid, effective half-life is approximately 2-5 hours due to clearance by the reticuloendothelial system |
| Protein binding | Negligible protein binding; free pertechnetate is not protein bound; colloid particles are phagocytosed by macrophages |
| Volume of Distribution | Vd is approximately 0.2-0.3 L/kg for the colloid, reflecting distribution primarily in blood pool and reticuloendothelial organs (liver, spleen, bone marrow) |
| Bioavailability | Not applicable for intravenous or subcutaneous routes; oral bioavailability is negligible (<1%) due to degradation in GI tract |
| Onset of Action | IV injection: immediate; local lymphoscintigraphy: 15-30 minutes; oral administration: minimal absorption; no clinical effect |
| Duration of Action | Imaging useful for up to 2-4 hours post-injection; radionuclide decay reduces activity over 24 hours; hepatic uptake peaks at 10-20 minutes and persists for several hours |
1-8 mCi (37-296 MBq) intravenously for liver/spleen imaging; 0.5-4 mCi (18.5-148 MBq) subcutaneously for lymphoscintigraphy; 0.5-4 mCi (18.5-148 MBq) instilled intraperitoneally for peritoneal shunt patency; 1-4 mCi (37-148 MBq) orally for gastric emptying study.
| Dosage form | SOLUTION |
| Renal impairment | No specific dose adjustment is recommended; however, consider reducing dose in severe renal impairment (GFR <30 mL/min/1.73m²) due to prolonged retention. |
| Liver impairment | No specific dose adjustment is recommended; use with caution in Child-Pugh Class C due to altered biodistribution. |
| Pediatric use | Weight-based: 0.05-0.1 mCi/kg (1.85-3.7 MBq/kg) intravenously for liver/spleen imaging, minimum 0.5 mCi (18.5 MBq); for lymphoscintigraphy: 0.05-0.1 mCi/kg subcutaneously, maximum 1 mCi (37 MBq). |
| Geriatric use | No specific dose adjustment required; consider reduced dose in elderly patients with compromised renal function, using adult dosing range at lower end (1-4 mCi intravenously). |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TECHNETIUM TC 99M SULFUR COLLOID (TECHNETIUM TC 99M SULFUR COLLOID).
| Breastfeeding | Tc-99m sulfur colloid has a short physical half-life (6 hours) and is minimally excreted into breast milk (estimated M/P ratio < 0.1). The radiation dose to the nursing infant is negligible (<0.01 mSv). According to the ACR, breastfeeding can be continued without interruption after administration. |
| Teratogenic Risk | Tc-99m sulfur colloid is a diagnostic radiopharmaceutical. Fetal radiation exposure during the first trimester (organogenesis) is associated with a small increase in the risk of malformation (estimated excess risk <0.01% per mGy). Second and third trimester exposure carries low risk for deterministic effects (mental retardation) at typical diagnostic doses (<0.1 mGy). No teratogenic drug-specific effects; risk is solely radiation-related. |
■ FDA Black Box Warning
No FDA black box warning is present for this drug.
| Serious Effects |
["Known hypersensitivity to technetium Tc 99m sulfur colloid or any component","Pregnancy: use only if potential benefit outweighs risk","Breastfeeding: avoid unless necessary; consider interruption"]
| Precautions | ["Risk of hypersensitivity or allergic reactions, including anaphylaxis","Radiation exposure risk; use minimal effective dose","Pregnancy: caution; fetal radiation exposure should be minimized","Lactation: potential for radioactivity in breast milk; consider temporary cessation","Injection site reactions: pain, inflammation, or extravasation","Use caution in patients with hepatic or splenic impairment; altered biodistribution may occur","Ensure radiopharmaceutical purity; improper preparation may affect imaging"] |
Loading safety data…
| Fetal Monitoring | No specific maternal monitoring required. In pregnant patients, confirm pregnancy status and document estimated fetal radiation dose. Post-administration, no fetal monitoring indicated. |
| Fertility Effects | No known effect on fertility from Tc-99m sulfur colloid. Radiation exposure to gonads is minimal at diagnostic doses. |